Canada – Healthcare, Regulatory and Reimbursement Landscape

All the vital news, analysis, and commentary curated by our industry experts.

$1995

Buy Report Download FREE Resources

Published: January 20, 2022 Report Code: GDHC0023CHR-ST

Report Overview
Table of Contents
Table
Figures

GlobalData, the industry analysis specialist, has released its latest report: “Canada – Healthcare, Regulatory and Reimbursement Landscape”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Canada. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.
The growth in Canada’s pharmaceutical market is attributed to the adoption of R&D activities towards advanced therapies and increased partnerships among pharmaceutical companies and academia, small and medium-sized enterprises (SMEs), government, and research centers. In 2020, the Canadian pharmaceutical market was the ninth largest globally in terms of value. Canada’s pharmaceutical market, based on production value, $23.86 billion in 2013 increased to $25.55 billion in 2020 at a Compound Annual Growth Rate (CAGR) of 0.98%. It is forecast to reach about $27.08 billion in 2026. In 2016, the medical devices market in Canada was worth $8.02 billion, which increased at a CAGR of 6.09% to $10.79 billion in 2021. It is expected to grow at a CAGR of 3.96% from 2022 to reach $12.96 billion in 2027.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Canada, and includes:

•An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.

•Profiles and SWOT analyses of the major players in the pharmaceutical market: Johnson & Johnson, Novartis, Abbvie, Ceapro, and Thera technologies.

•Profiles and SWOT analyses of the major players in the medical device market: Abbott, Medtronic, Boston Scientific, Bausch Health, and AlphaProTech.

•An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices.

•Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure.

•An overview of the opportunities for and challenges to growth in the Canadian healthcare market.

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

•Develop business strategies by understanding the trends shaping and driving Canadian healthcare market

•Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Canadian healthcare market in the future

•Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

•Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights – Facts about the Canadian Healthcare Market

2.3 Key Highlights: Healthcare Startups in Canada

2.4 Key Events: Canadian Healthcare Timeline, 2015–2021

2.5 Key Events: Canadian Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020–2021

2.7 Key Events: Top Completed Deals by Value, 2020–2021

2.8 Country Profile, Canada, 2020

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Canada

3.5 Pharmaceutical Market – Market Segments

3.6 Pharmaceutical Market – Market Segment, Generics, Canada

3.7 Pharmaceutical Market – Market Segment, Biologics and Biosimilars, Canada

3.8 Pharmaceutical Market – Market Segment, Over-the-Counter Medicines, Canada

3.9 Major Therapeutic Areas, Canada

3.10 COVID-19 Epidemiology, Canada

3.11 COVID-19 Impact and Developments in the Healthcare Market, Canada

3.12 Covid-19 Clinical Trials Landscape, Canada

3.13 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Canada, 2020–2021

6.2 Deal Analysis: Medical Device Market, Canada, 2020–2021

7. HealthTech Landscape

7.1 HealthTech Landscape, Canada

7.2 HealthTech Deals Landscape, Canada

7.3 Key HealthTech Deals, Canada

7.4 Adoption of Technology in Healthcare, Canada

7.5 Regulatory Scenario Covering Use of Technology in Healthcare, Canada

7.6 HealthTech Landscape: Benefits and Risks, Canada

8. Market Access

8.1 Overview of Healthcare System, Canada

8.2 Reimbursement of Pharmaceutical Products, Canada

8.3 Reimbursement of Medical Devices, Canada

8.4 Overview of Insurance Providers, Public Insurance, Canada

8.5 Overview of Insurance Providers, Private Insurance, Canada

8.6 Healthcare Spending and Prescription Drug Price Trend, Canada

8.7 Pricing Policies, Canada

8.8 Regulatory Landscape, Canada

8.8.1 Marketing Authorization for Pharmaceutical Products, Canada

8.8.2 Marketing Authorization for Medical Devices, Canada

8.8.3 Intellectual Property Rights, Patent, Canada

8.8.4 Intellectual Property Rights, Trademark, Canada

8.8.5 Clinical Trial Regulation Process, Canada

8.8.6 Pharmaceutical Clinical Trials Landscape, Canada

8.8.7 Medical Devices Clinical Trials Landscape, Canada

8.8.8 Pharmaceutical Export and Import, Canada

8.8.9 Pharmaceutical Advertising Regulations, Canada

8.8.10 Pharmacy Regulations, Canada

8.8.11 Labeling and Packaging Regulations, Canada

9. Country Healthcare Landscape

9.1 Canadian Healthcare Policy Highlights

9.2 Healthcare Facilities, Canada

9.3 Healthcare Parameters, Canada

9.4 Life Expectancy and Immunization Rate, Canada

9.5 Environmental Health, Canada

9.6 Healthcare Personnel, Canada

9.7 Disease Burden, Canada

9.8 Healthcare Expenditure, Canada

10 Trade Associations, Canada

11 Trade Fairs, Canada

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Approved Biosimilars, Canada 2020–2021

Table 2: Major Therapeutic Areas by Production Value ($B), Canada, 2020

Table 3: COVID-19 Indicators (Number of Cases), Global and Canada, 2020–2021

Table 4: COVID-19-Related Travel Restrictions, Canada, 2020–2021

Table 5: Authorized COVID-19 Vaccines, Canada, 2020–2021

Table 6: List of Authorized Treatments for COVID-19, Canada, 2020-2021

Table 7: Total COVID-19 Vaccine Distribution Canada, 2021

Table 8: COVID-19 IVD Products (December ‘20- December ‘21), Canada, 2020–2021

Table 9: Medical Device Market, Canada, Major Segments ($B), 2021

Table 10: Orthopedic Devices Market, Canada, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 11: General Surgery Market, Canada, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 12: Hospital Supplies Market, Canada, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 13: Cardiovascular Devices Market, Canada, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 14: Diabetes Care Devices Market, Canada, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 15: AI/ML Medical Devices Approved by Health Canada, Canada, 2020-2021

Table 16: List of Provincial Insurance Programs, Canada, 2021

Table 17: TPF, Pricing Tiers, Canada, 2021

Table 18: Fees for Examination of Drug Submission, Canada, 2021

Table 19: Fees for Right to Sell Drugs, Canada, 2021

Table 20: Classification and Regulation Regarding Medical Devices, Canada, 2021

Table 21: Fees for Examination of Medical Devices License Application, Canada, 2021

Table 22: Fees for Right to Sell Medical Devices, Canada, 2021

Table 23: Patent Fees, Canada, 2021

Table 24: Trademark Fees, Canada, 2021

Table 25: Importation Requirements for Health Products in Canada

Table 26: Trade Fairs, Canada

Figures

Figure 1: Pharmaceutical Market, Canada, Revenue ($B and CADB), 2013–2020

Figure 2: Medical Devices Market, Canada, Revenue ($B), 2016–2021

Figure 3: Healthcare Startups in Canada, 2021

Figure 4: Country Profile, Canada, 2020

Figure 5: Pharmaceutical Market, Canada, Revenue ($B and CADB), 2013–2020

Figure 6: Pharmaceutical Market, Canada, Revenue Forecast ($B and CADB), 2021–2026

Figure 7: Pharmaceutical Exports ($B), Canada, 2013–2020

Figure 8: Top Export Partners, Canada, 2020

Figure 9: Pharmaceutical Imports ($B), Canada, 2013–2020

Figure 10: Top Import Partners, Canada, 2020

Figure 11: Pharmaceutical Market, Supply Channel, Canada, 2021

Figure 12: Generic Share by Value (%), Canada, 2013–2020

Figure 13: Generic Share by Volume (%), Canada, 2013–2020

Figure 14: OTC Medicines Market, Major Distribution Channels ($B), Canada, 2020

Figure 15: OTC Medicines Market, Revenue ($B), Canada, 2013–2020

Figure 16: OTC Medicines Market, Major Categories ($M), Canada, 2020

Figure 17: Major Therapeutic Areas by Production Value, Canada, 2020

Figure 18: COVID-19 Cases, Canada, 2020–2021

Figure 19: COVID-19 Deaths, Canada, 2020–2021

Figure 20: COVID-19 Fiscal Stimulus Timeline, Canada, 2020–2021

Figure 21: COVID-19 Vaccine Doses Administration, Number of Vaccine Doses Administered, Canada, 2021

Figure 22: COVID-19 Clinical Trials Count by Market Categories, Canada, 2020–2021

Figure 23: COVID-19 Clinical Trials Count by Trial Status, Canada, 2020–2021

Figure 24: Top COVID-19 Clinical Trials Sponsors by Trial Count, Canada, 2020–2021

Figure 25: Medical Devices Market, Canada, Revenue ($B), 2016–2021

Figure 26: Medical Devices Market, Canada, Revenue Forecast ($B), 2022–2027

Figure 27: Medical Device Market, Canada, Major Segments (%), 2021

Figure 28: Orthopedic Devices Market, Canada, Revenue ($B), 2017–2025

Figure 29: Orthopedic Devices Market, Canada, Market Share of Major Players (%), 2020

Figure 30: General Surgery Market, Canada, Revenue ($B), 2017–2025

Figure 31: General Surgery Market, Canada, Market Share of Major Players (%), 2020

Figure 32: Hospital Supplies Market, Canada, Revenue ($B), 2017–2025

Figure 33: Hospital Supplies Market, Canada, Market Share of Major Players (%), 2020

Figure 34: Cardiovascular Devices Market, Canada, Revenue ($B), 2017–2025

Figure 35: Cardiovascular Devices Market, Canada, Market Share of Major Players (%), 2020

Figure 36: Diabetes Care Devices Market, Canada, Revenue ($B), 2017–2025

Figure 37: Diabetes Care Devices Market, Canada, Market Share of Major Players (%), 2020

Figure 38: Diagnostics Market, Canada, Revenue ($B), 2015–2020

Figure 39: Diagnostics Market, Canada, Revenue Forecast ($B), 2021–2025

Figure 40: Medical Devices Market, Revenue ($B) of Major Companies, Canada, 2020

Figure 41: Deal Value and Deal Count, Pharmaceutical Market, Canada, 2020–2021

Figure 42: Deal Value and Deal Count Sub-types, Pharmaceutical Market, Canada, 2020–2021

Figure 43: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, Canada, 2020–2021

Figure 44: Top Five Therapy Areas by Deal Value, Pharmaceutical Market, Canada, 2020–2021

Figure 45: Top Five Therapy Areas by Deal Count, Pharmaceutical Market, Canada, 2020–2021

Figure 46: M&A Deals by Quarter, Pharmaceutical Market, Canada, 2020–2021 (by Value and by Number)

Figure 47: VC Deals by Quarter, Pharmaceutical Market, Canada, 2020–2021 (by Value and by Number)

Figure 48: Deal Value and Deal Count, Medical Devices Market, Canada, 2020–2021

Figure 49: Deal Value and Deal Count Sub-types, Medical Devices Market, Canada, 2020–2021

Figure 50: Deal Value and Deal Count, Quarterly, Medical Devices Market, Canada, 2020–2021

Figure 51: Top Equipment Areas by Deal Value ($B), Medical Devices Market, Canada, 2020–2021

Figure 52: Top Equipment Areas by Deal Count, Medical Devices Market, Canada, 2020–2021

Figure 53: M&A Deals by Quarter, Medical Devices Market, Canada, 2020–2021 (by Value and by Number)

Figure 54: VC Deals by Quarter, Medical Devices Market, Canada, 2020–2021 (by Value and by Number)

Figure 55: Key Areas of Focus, Digital Technology Supercluster, Canada, 2020

Figure 56: Top Digital Innovations, Canada, 2021

Figure 57: Objectives of Pan-Canadian AI Strategy, 2017

Figure 58: Deal Value ($M), HealthTech, Canada, 2020–2021

Figure 59: Deal Count (No. of Deals), HealthTech, Canada, 2020–2021

Figure 60: Adoption of Technology in Healthcare, Canada

Figure 61: Principles of Digital Charter Implementation Act, Canada, 2020

Figure 62: Organization of the Health System, Canada, 2020

Figure 63: Canadian Health Databases Managed by CIHI, Canada, 2021

Figure 64: Common Drug Review Process, Canada, 2020

Figure 65: Pan-Canadian Oncology Drug Review Process, Canada, 2020

Figure 66: INESSS Evaluation Process For Registration, Canada, 2020

Figure 67: Drug Reimbursement Process, Canada, 2020

Figure 68: Medical Devices Reimbursement Process, Canada, 2020

Figure 69: Private Insurance Coverage, Canada, 2013-2020

Figure 70: OOP Expenditure (% of Total Expenditure on Health), Canada, 2013–2020

Figure 71: Annual Rate of Change (%), Consumer Price Index, Healthcare Products (Base Year 2002=100), Canada, 2013–2020

Figure 72: HPFB Organizational Structure, Canada, 2019

Figure 73: CTD Format, Canada, 2020

Figure 74: New Drug Approval Process, Canada, 2020

Figure 75: New Medical Device Approval Process, Canada, 2021

Figure 76: Patent Registration Process, Canada, 2021

Figure 77: Trademark Registration Process, Canada, 2021

Figure 78: Clinical Trial Regulation Process, Canada, 2021

Figure 79: Pharmaceutical Clinical Trials Count by Trial Status, Canada, 2020–2021

Figure 80: Pharmaceutical Clinical Trials Count by Therapy Areas, Canada, 2020–2021

Figure 81: Pharmaceutical Clinical Trials Count by Phase, Canada, 2020–2021

Figure 82: Top Five Pharmaceutical Clinical Trial Sponsors by Count, Canada, 2020–2021

Figure 83: Medical Devices Clinical Trials Count by Trial Status, Canada, 2020–2021

Figure 84: Medical Devices Clinical Trials Count by Indication, Canada, 2020–2021

Figure 85: Medical Devices Clinical Trials Count by Category, Canada, 2020–2021

Figure 86: Top Five Medical Devices Clinical Trial Sponsors by Count, Canada, 2020–2021

Figure 87: PAAB Approval Process, Canada, 2021

Figure 88: Digital Health Canada Strategy 2023

Figure 89: Number of Hospitals, Canada, 2012–2019

Figure 90: Number of Diagnostic Equipment, Canada, 2012–2019

Figure 91: Acute Care Hospital Beds (per 1,000 population), Canada, 2013–2019

Figure 92: Hospital Beds (per 1,000 population), Canada, 2013–2019

Figure 93: Psychiatric Care Hospital Beds (per 1,000 population), Canada, 2013–2019

Figure 94: Immunization Rate (%), Canada, 2012–2018

Figure 95: Life Expectancy at Birth (Years), Canada, 2012–2019

Figure 96: CO2 Emissions (Million Tons), Canada, 2013–2020

Figure 97: PM2.5 (µg per m3), Canada, 2013–2019

Figure 98: Physicians (per 1,000 population), Canada, 2013–2020

Figure 99: Pharmacists (per 1,000 population), Canada, 2013–2019

Figure 100: Dentists (per 1,000 population), Canada, 2013–2019

Figure 101: Nurses (per 1,000 population), Canada, 2013–2019

Figure 102: Major Causes of Mortality (per 100,000 population), Canada, 2019

Figure 103: Major Causes of Male Mortality (per 100,000 population), Canada, 2019

Figure 104: Major Causes of Female Mortality (per 100,000 population), Canada, 2019

Figure 105: DALYs by Major Disease (per 100,000 population), Canada, 2019

Figure 106: Healthcare Expenditure as Percentage of GDP (%), Canada, 2013–2019

Figure 107: Health Expenditure Share (% of Total Health Spending), Canada, 2013–2019

Figure 108: Pharmaceutical Spending (% of Total Health Spending), Canada, 2013–2019

Figure 109: Healthcare Expenditure Components by Function (% of Total Health Expenditure), Canada, 2019

Figure 110: Opportunities and Challenges

Frequently asked questions

Currency USD

Single User

$1,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Canada – Healthcare, Regulatory and Reimbursement Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports

Pharmaceuticals

New

Global M&A Deals in H1 2026 - Top Themes by…

Pharmaceuticals

New

Pharmaceutical Drug Development Annual Review 2025

Pharmaceuticals

New

Q2 2026 CRO Activity and Intel Report

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Canada – Healthcare, Regulatory and Reimbursement Landscape in real time.

Access a live Canada – Healthcare, Regulatory and Reimbursement Landscape dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Canada – Healthcare, Regulatory and Reimbursement Landscape

Scope

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports